Alivus Life Sciences Ltd (ALIVUS)
₹1,391.80
Mkt cap
₹16,774 Cr
P/E ratio
27.00
P/B
5.14
Div yield
0.37%
ROE
17.90%
ROCE
23.80%
EPS (TTM)
₹51.55
Book value
₹271
52W range
860–1,444
Sector
Healthcare
Price history
Previous close
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.
NSE ALIVUSBSE 543322
Health check
Constructive
ValuationCheap
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−3.59% from high₹1,392
₹860+61.83% from low₹1,444
Current
₹1,391.80
Prev close
₹1,369.90
Day
+1.60%
Price performance
1D
+1.60%
1W
−0.99%
1M
+4.66%
3M
+34.47%
6M
+52.79%
1Y
+48.62%
YTD
+52.44%
Financials
Revenue, profit & margin
P/E ratio
27.0×
ALIVUS is 20% below the sector median of 34.0×
ALIVUS27.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 | |
| Expenses | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 | |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 | |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% | |
| Other Income | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 | |
| Profit before tax | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 | |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% | |
| Net Profit | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 | |
| EPS in Rs | 11.05 | 9.69 | 9.69 | 7.99 | 9.10 | 7.78 | 11.18 | 11.58 | 9.91 | 10.60 | 12.25 | 13.25 | 13.04 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.13% · closed higher next day 10 of last 20
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 20 Oct '23◦ | 23 Jan '24◦ | 25 Apr '24◦ | 25 Jul '24◦ | 24 Oct '24◦ | 23 Jan '25◦ | 15 May '25◦ | 1 Aug '25◦ | 6 Nov '25◦ | 22 Jan '26 | 14 May '26◦ | 30 Jul '26◦ |
| Earnings day | −0.75% | +1.18% | +8.59% | −2.92% | −9.86% | −1.52% | −5.26% | −3.49% | +2.76% | +0.02% | −1.83% | +5.87% |
| +1 day | −1.07% | +5.82% | +9.15% | −0.63% | −5.95% | +2.62% | −5.10% | −1.39% | +3.38% | +2.58% | −0.83% | +10.83% |
| +5 days | +0.20% | +8.42% | +10.72% | +0.88% | +3.11% | +2.85% | −7.38% | −7.32% | +1.59% | +11.58% | −2.36% | +21.37% |
| +15 days | +1.11% | +10.82% | +9.60% | +13.46% | +4.02% | −12.07% | −16.58% | −5.21% | +0.90% | +6.79% | −5.84% | +23.29% |
| +30 days | +1.84% | −3.13% | +16.79% | +37.51% | +0.85% | −7.54% | −16.97% | −6.16% | +1.14% | +6.79% | +8.68% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jun 202674.87%Promoter
Promoters74.87%
FIIs5.54%0.24
DIIs7.18%0.09
Public12.42%0.13
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| ALIVUS | ₹1,366.30 | 26.98 | 16,774 | 0.37% | 160 | +31.71% | 640 | +6.41% | 23.79% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports6
Concall transcripts47
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025TranscriptJan 2025PPTJan 2025RECJan 2025TranscriptOct 2024PPTOct 2024RECOct 2024TranscriptAug 2024PPTAug 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 5 SepAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 25 Aug - Alivus Life Sciences will hold four one-on-one investor meetings from August 28 to September 2, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 18 Aug - Alivus Life Sciences to acquire 76% stake in IQGenX for INR 91.2 million, closing expected by year-end.Announcement under Regulation 30 (LODR)-Acquisition 18 Aug - Board approved 76% stake acquisition in IQGEN-X Pharma for about Rs 9.12 crore.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Aug - Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting